A decade of exploring the cancer epigenome -biological and translational implications, Nat Rev Cancer, vol.11, issue.10, pp.726-734, 2011. ,
A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis, Ann Oncol, vol.24, issue.8, pp.2048-2056, 2013. ,
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype, Proc Natl Acad Sci, vol.97, issue.2, pp.710-715, 2000. ,
Hypermethylator www.impactjournals.com/oncotarget phenotype in sporadic colon cancer: study on a populationbased series of 582 cases, Cancer Res, vol.68, issue.20, pp.8541-8546, 2008. ,
Cancer statistics, CA Cancer J Clin, vol.65, issue.1, pp.5-29, 2015. ,
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma, Virchows Arch, vol.450, issue.5, pp.529-537, 2007. ,
Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy, Clin Cancer Res, vol.13, issue.20, pp.6093-6098, 2007. ,
Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability, J Clin Oncol, vol.21, issue.20, pp.3729-3736, 2003. ,
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progressionfree survival in patients and identifies candidate epigenetic markers, Clin Cancer Res, vol.8, issue.7, pp.2246-2252, 2002. ,
Epigenetics as a mechanism driving polygenic clinical drug resistance, Br J Cancer, vol.94, issue.8, pp.1087-1092, 2006. ,
5-aza-2'-deoxycytidine sensitizes hepatoma and pancreatic cancer cell lines, Oncol Rep, vol.14, issue.4, pp.975-979, 2005. ,
SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2'deoxycytidine to increase SPARC expression and improve therapy response, Br J Cancer, vol.98, issue.11, pp.1810-1819, 2008. ,
A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer, Anticancer Res, vol.27, issue.3B, pp.1449-1452, 2007. ,
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter, Cancer Res, vol.60, issue.21, pp.6039-6044, 2000. ,
Epigenetic synergy between decitabine and platinum derivatives, Clin Epigenetics, vol.7, issue.1, p.97, 2015. ,
A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors, Ann Oncol, vol.18, issue.9, pp.1529-1538, 2007. ,
A phase IIa study of sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patietns with platinum resistant or refracoty epithelial ovarian cancer, J Clin Oncol (Meeting Abstracts), vol.26, pp.15-3500, 2008. ,
Phase I study of azacitidine and cisplatin in patients with advanced head and neck or non-small cell lung cancer, Proceedings of the 103rd Annual Meeting of the, 2012. ,
, Abstract nr 2663 doi, vol.72, pp.1538-7445, 2012.
Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer, Cancer Discov, vol.1, issue.7, pp.598-607, 2011. ,
Sensitive digital quantification of DNA methylation in clinical samples, Nat Biotechnol, vol.27, issue.9, pp.858-863, 2009. ,
Highly methylated genes in colorectal neoplasia: implications for screening, Cancer Epidemiol Biomarkers Prev, vol.16, issue.12, pp.2686-2696, 2007. ,
Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene, J Natl Cancer Inst, vol.97, issue.15, pp.1124-1132, 2005. ,
Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas, Clin Cancer Res, vol.15, issue.11, pp.3881-3888, 2009. ,
Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin www.impactjournals.com/oncotarget in solid tumors, J Clin Oncol, vol.25, issue.29, pp.4603-4609, 2007. ,
,
, Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy, Clin Epigenetics, vol.7, issue.1, p.29, 2015.
Phase I trial of continuous infusion 5-aza-2'-deoxycytidine, Cancer chemotherapy and pharmacology, vol.51, issue.3, pp.231-239, 2003. ,
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, doseescalation phase 1 study, Lancet Oncol, vol.16, issue.9, pp.1133-1142, 2015. ,
Results of a randomized study of 3 schedules of lowdose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, Blood, vol.109, issue.1, pp.52-57, 2007. ,
Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability, Leuk Res, vol.30, issue.3, pp.338-342, 2006. ,
A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines, PloS one, vol.5, issue.2, p.9001, 2010. ,
Epigenetic and genetic features of 24 colon cancer cell lines, Oncogenesis, vol.2, p.71, 2013. ,
BiSearch: primer-design and search tool for PCR on bisulfite-treated genomes, Nucleic acids research, vol.33, issue.1, p.9, 2005. ,
The BiSearch web server, BMC bioinformatics, vol.7, p.431, 2006. ,
Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis, BMC Bioinformatics, vol.11, p.587, 2010. ,
, Comprehensive molecular characterization of human colon and rectal cancer, Nature, vol.487, issue.7407, pp.330-337, 2012.
A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements, Nucleic Acids Res, vol.32, issue.3, p.38, 2004. ,
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies, Blood, vol.103, issue.5, pp.1635-1640, 2004. ,